Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 14/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136016 | 0.89 | CD38 (0.67) | CD38CYP1A2KMT2ACYP3A4CYP2D6 | |
| SCHEMBL25135984 | 0.88 | CD38 (0.69) | CD38GAACYP1A2KMT2ACYP3A4 | |
| SCHEMBL25135864 | 0.87 | CD38 (0.56) | CD38GAACYP1A2KMT2ACYP3A4 | |
| SCHEMBL25135679 | 0.87 | POLB (0.59) | CD38GAACYP1A2KMT2ACYP3A4 | |
| SCHEMBL25135562 | 0.86 | CD38 (0.61) | CD38GAACYP1A2KMT2ACYP3A4 | |
| SCHEMBL25135819 | 0.86 | CD38 (0.72) | CD38GAAKMT2ACTSASMN1; SMN2 | |
| SCHEMBL30363751 | 0.86 | CD38 (0.55) | CD38GAACYP1A2KMT2ACYP2C19 | |
| SCHEMBL25135823 | 0.86 | CD38 (0.55) | CD38GAACYP1A2KMT2ACYP2C19 | |
| SCHEMBL30040575 | 0.85 | CD38 (0.69) | CD38GAACYP1A2KMT2ACYP3A4 | |
| SCHEMBL25135998 | 0.84 | CD38 (0.53) | CD38GAACYP1A2KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885GAA 937/4885CYP1A2 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.